Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 217S · 10 late217 trades$54.77M
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
MTDRMatador Resources CoNov 5 – Nov 98 insiders$625K
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
IBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
BBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 21 | Mat IshbiaDirector, President and CEO, 10% Owner |  UWMCUWM Holdings CorpOpen-market sale · 10b5-1 plan | SELL | $3.20M 632.9K sh | Feb 4, 2026 |
| 20 | Schwartz Richard ToddDirector, Chief Executive Officer |  RSIRush Street Interactive, Inc.Open-market sale · 10b5-1 plan | SELL | $4.35M 247.1K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 20 | Malenka Robert C.Director |  MPLTMapLight Therapeutics, Inc.Open-market sale | SELL | $127K 7,039 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $378K 1,639 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 19 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $187K 4,064 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $186K 1,233 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $106K 720 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 18 | Howse CurtisSee remarks |  SYFSynchrony FinancialOpen-market sale · 10b5-1 plan | SELL | $3.80M 52.6K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malabre Richard CSVP, Chief Accounting Officer |  AKBAAkebia Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $50K 36.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malenka Robert C.Director | MPLTMapLight Therapeutics, Inc. Open-market sale | SELL | $18 1 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $202K 878 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $140K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Stetz MattiasChief Operating Officer | RSIRush Street Interactive, Inc. Open-market sale · 10b5-1 plan | SELL | $353K 20.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $133K 576 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $197K 850 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Schafer JoshuaCCO |  ZVRAZEVRA THERAPEUTICS, INC.Open-market sale · 10b5-1 plan | SELL | $97K 10.5K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 13 | Sharma ManishChief Strategy & Services Ofcr | ACNAccenture plc Open-market sale · 10b5-1 plan | SELL | $25K 98 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 13 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $18K 80 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $3,744 16 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Wampler Kira SchererDirector |  DOCSDoximity, Inc.Open-market sale · 10b5-1 plan | SELL | $75K 2,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 12 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $34K 736 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 11 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $27K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 11 | Holleran KevinDirector, President and CEO |  HAYWHayward Holdings, Inc.Open-market sale · 10b5-1 plan | SELL | $841K 52.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Rucci Carolyn M.SVP, Chief Legal Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $38K 27.5K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Rucci Carolyn M.SVP, Chief Legal Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $23K 16.8K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Malabre Richard CSVP, Chief Accounting Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $19K 13.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Alpern Paul LVP and General Counsel |  AIPArteris, Inc.Open-market sale · 10b5-1 plan | SELL | $77K 5,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Rucci Carolyn M.SVP, Chief Legal Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $35K 25.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 9 | Feierstein Matthew DavidPresident |  EVCMEverCommerce Inc.Open-market sale · 10b5-1 plan | SELL | $121K 10.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 9 | Feierstein Matthew DavidPresident | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $102K 9,280 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 8 | Okupe OluyemiChief Financial Officer |  HIMSHims & Hers Health, Inc.Open-market sale · 10b5-1 plan | SELL | $139K 5,262 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 8 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $8,830 200 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 8 | Gummadi SuryaPresident - Americas | CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP Open-market sale · 10b5-1 plan | SELL | $144K 1,728 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 6 | Feierstein Matthew DavidPresident | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $108K 10.0K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 6 | Feierstein Matthew DavidPresident | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $8,388 720 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 6 | Remer Eric RichardDirector, Chief Executive Officer | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $159K 14.7K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 5 | Vultaggio VincentPAO and PFO |  ZNTLZentalis Pharmaceuticals, Inc.Open-market sale · 10b5-1 plan | SELL | $6,477 2,540 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 5 | Saldanha CraigChief Product Officer |  YELPYELP INCOpen-market sale · 10b5-1 plan | SELL | $33K 1,200 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 3 | Remer Eric RichardDirector, Chief Executive Officer | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $30K 2,797 sh | Feb 4, 2026 traded Feb 4, 2026 |
| 3 | Remer Eric RichardDirector, Chief Executive Officer | EVCMEverCommerce Inc. Open-market sale · 10b5-1 plan | SELL | $20K 1,700 sh | Feb 4, 2026 traded Feb 3, 2026 |